Friday, 17 July 2026
  
Login

Australia's most trusted
source of pharma news

Friday, 17 July 2026
News

MS drugs delisting threat ends

Posted 17 July 2026 AM

The threat that two PBS drugs for MS could be delisted following a Government-requested price cut of 40 per cent has been averted with Health Minister Mark Butler announcing late last night that the medicines would continue to be reimbursed.

The two drugs - Roche's Ocrevus and Novartis' Kesimpta - are used to treat half the MS patients in Australia. The possibility of a delisting has caused a political headache for the Government for more than two weeks after Butler failed to use his ministerial powers to rule out a delisting.

To see the whole article, please login


Latest Jobs
Pharma in Focus  Jobs

Marketing & Communications (1)

Sales & Customer Relations (23)

Access & Reimbursement (1)

Clinical & Medical, R&D (9)

Regulatory, Pharmacovigilance & QA (3)

Other (12)

MORE NEWS
Email this article to a friend
From:

 
 
  
Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

 

You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.